BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mónica FZ, De Nucci G. Tadalafil for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother 2019;20:929-37. [PMID: 30901259 DOI: 10.1080/14656566.2019.1589452] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Awad AK, Gad ER, Abdelgalil MS, Elsaeidy AS, Ahmed O, Elseidy SA. Sildenafil for congenital heart diseases induced pulmonary hypertension, a meta-analysis of randomized controlled trials.. [DOI: 10.21203/rs.3.rs-1871438/v1] [Reference Citation Analysis]
2 陶 俊. Current Status of Drug Therapy for Benign Prostatic Hyperplasia. ACM 2022;12:10146-10151. [DOI: 10.12677/acm.2022.12111463] [Reference Citation Analysis]
3 Sugianto R, Tirtayasa P, Duarsa G. A comprehensive review of medical therapy on benign prostatic hyperplasia. Sexologies 2022;31:52-60. [DOI: 10.1016/j.sexol.2021.07.002] [Reference Citation Analysis]
4 Cui J, Cao D, Bai Y, Wang J, Yin S, Wei W, Xiao Y, Wang J, Wei Q. Efficacy and Safety of 12-week Monotherapy With Once Daily 5 mg Tadalafil for Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: Evidence-based Analysis. Front Med (Lausanne) 2021;8:744012. [PMID: 34712682 DOI: 10.3389/fmed.2021.744012] [Reference Citation Analysis]
5 Zhang M, Luo C, Lin D, Cui K, Chen Z, Liu J. Human Tissue Kallikrein 1 Is Downregulated in Elderly Human Prostates and Possesses Potential In Vitro Antioxidative and Antifibrotic Effects in Rodent Prostates. Oxid Med Cell Longev 2021;2021:8877540. [PMID: 34007408 DOI: 10.1155/2021/8877540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lee WC, Leu S, Wu KLH, Tain YL, Chuang YC, Chan JYH. Tadalafil ameliorates bladder overactivity by restoring insulin-activated detrusor relaxation via the bladder mucosal IRS/PI3K/AKT/eNOS pathway in fructose-fed rats. Sci Rep 2021;11:8202. [PMID: 33859259 DOI: 10.1038/s41598-021-87505-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Passos GR, Ghezzi AC, Antunes E, de Oliveira MG, Mónica FZ. The Role of Periprostatic Adipose Tissue on Prostate Function in Vascular-Related Disorders. Front Pharmacol 2021;12:626155. [PMID: 33643052 DOI: 10.3389/fphar.2021.626155] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
8 Fang T, Xue ZS, Li JX, Liu JK, Wu D, Li MQ, Song YT, Yun SF, Yan J. Rauwolfia vomitoria extract suppresses benign prostatic hyperplasia by reducing expression of androgen receptor and 5α-reductase in a rat model. J Integr Med 2021;19:258-64. [PMID: 33341427 DOI: 10.1016/j.joim.2020.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Painter CE, Suskind AM. Advances in pharmacotherapy for the treatment of overactive bladder. Curr Bladder Dysfunct Rep 2019;14:377-84. [PMID: 33312325 DOI: 10.1007/s11884-019-00562-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
10 de Oliveira IP, Lescano CH, De Nucci G. In Silico Mapping of Essential Residues in the Catalytic Domain of PDE5 Responsible for Stabilization of Its Commercial Inhibitors. Sci Pharm 2019;87:29. [DOI: 10.3390/scipharm87040029] [Reference Citation Analysis]
11 Negoro H, Goto T, Akamatsu S, Terada N, Kobayashi T, Matsui Y, Yamamoto T, Omura T, Yonezawa A, Matsubara K, Ogawa O. Add-on effects of tadalafil in tamsulosin-treated patients with small benign prostatic enlargement: A randomized, placebo-controlled, double-blind, crossover study. Neurourol Urodyn 2020;39:237-42. [PMID: 31578771 DOI: 10.1002/nau.24175] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]